Oncopeptides plans EMA filing to broaden Pepaxti indication

GSK partners with SBP Group to accelerate China launch of bepirovirsen

Harbour BioMed's HBM7004 receives US FDA IND clearance for Phase I trial

Mabwell's clinical trial application for 9MW5211 cleared by US FDA

Innovent's IBI363 receives third Chinese regulatory BTD for MSS/pMMR CRC

European Commission approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis

Rznomics receives FDA RMAT designation for HCC candidate RZ‑001

BioArctic and Eisai report FDA extension of Leqembi Iqlik review

Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD

Altasciences and Certara form strategic partnership to accelerate early drug development

Partner Therapeutics' BIZENGRI receives FDA Commissioner's National Priority Voucher for NRG1 fusion-positive cholangiocarcinoma

Diakonos Oncology's DOC1021 granted US FDA Fast Track Designation for unresectable or metastatic cutaneous melanoma

ZYUS Life Sciences receives second US pain management patent

Citius Oncology to accelerate LYMPHIR commercialisation with up to USD36.5m in debt and equity capital

Alebund Pharmaceuticals completes AP301 Phase III clinical trial patient enrolment for hyperphosphataemia